drugset
drugset / Trial / NCT07259317

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07259317 ↗

Phase 2 Recruiting 80 enrolled Corcept Therapeutics
NaSequentialOpen-labelTreatment

Summary

This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic adenocarcinoma (PDAC).

Timeline

Start
2026-01-27
Primary completion
2027-09
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule — Intravenous
Subject Paclitaxel Small molecule — Intravenous
Subject Relacorilant Small molecule — Oral

Indications

pancreatic ductal adenocarcinoma